In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction

Clinical Cancer Research

Volumn 7, Issue 1, 2001, Pages 202-209

  Kanzawa, Fumihiko ^a   Koizumi, Fumiaki ^a   Koh, Yasuhiro ^a   Nakamura, Takashi ^a   Tatsumi, Yasuaki ^a   Fukumoto, Hisao ^a   Saijo, Nagahiro ^b   Yoshioka, Takayuki ^c   Nishio, Kazuto ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 1 HYDROXYIRINOTECAN; CISPLATIN; CISPLATIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; NEDAPLATIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEPHROTOXICITY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL DIVISION; DNA TOPOISOMERASES, TYPE I; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED;

EID: 0035137615     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. cis-Diaminedichloroplatinum(II)
2. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer
3. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
4. cis-Platinum (CDDP) plus etoposide (VP-16-213) treatment of disseminated neuroblastoma
5. Carboplatin and etoposide in advanced colorectal carcinoma. A Phase II study
6. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer, Protocol 07861
7. cis-Dichlorodiamineplatinum(II) and etoposide for patients with refractory lymphomas
8. Clinical and pharmacological studies with cis-diaminedichloroplatinum(II)
9. Antitumor activity of a new platinum compound (glycolate-o, o') diaminedichloroplatinum(II) (254S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system
10. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell lung cancers of cis-diamineglucolatoplatinum (254S) and cis-diaminedichloroplatinum
11. Antitumor activity of 254S, a platinum complex, in rodents
12. Nephrotoxicity of a new platinum compound, 254S, evaluated with rat kidney cortical slices
13. Phase II study of cis-diamine(glycolato)platinum, 254S, in patients with advanced germ-cell carcinoma of the urinary tract
14. Phase II study of (glycolato-o, o') diamineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer
15. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of cell lines, SBC-3/NB
16. Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung cancer cell line, SBC-3
17. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
18. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines
19. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
20. Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei
21. Selective sensitization of Adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II α
22. Synergy of the combination of nedaplatin with etoposide in murine and human lung carcinoma
23. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
24. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues
25. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
26. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
27. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relaxation to antitumor activity
28. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells
29. Adducts of the antitumor drug cis-diaminedichloroplatinum(II) with DNA: Formation, identification, and quantitation
30. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diaminedichloroplatinum(II)
31. For the CPT-11 Lung Cancer Study Group. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer